Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00577629 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT00577629 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 39 participants.
The verdict
NCT00577629, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether using high-dose chemotherapy, monoclonal antibodies, and targeted radioimmunotherapy will slow the progression of disease in patients with high-risk Non-Hodgkin's Lymphoma (NHL).
Interventions
- DRUG cyclophosphamide
- DRUG doxorubicin
- DRUG etoposide
- DRUG rituximab
- DRUG cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2005-06-18 |
| Est. Completion | 2016-11-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00577629
The ClinicalTrials.gov registry entry for NCT00577629 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00577629 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00577629 about?
NCT00577629 is a clinical study titled "Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma". The purpose of this study is to determine whether using high-dose chemotherapy, monoclonal antibodies, and targeted radioimmunotherapy will slow the progression of disease in patients with high-risk Non-Hodgkin's Lymphoma (NHL).
What is the current status of trial NCT00577629?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2005-06-18. Estimated completion is 2016-11-03.
What interventions are being tested in trial NCT00577629?
The interventions under investigation include: cyclophosphamide (DRUG), doxorubicin (DRUG), etoposide (DRUG), rituximab (DRUG), cytarabine (DRUG).
Who is sponsoring clinical trial NCT00577629?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.